Journal News

Quantifying how proteins in microbe and host interact

Poornima Sankar
Nov. 20, 2024

Antimicrobial resistance is a growing problem around the world. When microbes such as bacteria, viruses, parasites and fungi stop responding to antimicrobial medicines, most researchers respond by working to develop new vaccines. However, when host proteins bind to bacterial proteins, that binding masks some dominant antigenic sites on the pathogen. Because of this, traditional vaccines have seen poor antibody responses. 

In a recent published in the journal Molecular & Cellular Proteomics,  researchers at Lund University used affinity purification combined with quantitative mass spectrometry, or AP-MS, techniques to investigate if these bacteria and host protein–protein interaction networks could compromise the development of protective antibody responses; they used Streptococcus pyogenes, a bacteria that causes infections in humans,as a model system.

was the corresponding author of this study. “To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” he said.

Streptococcus pyogenesbelongs to Group A Streptococcus, or GAS, which affects about 18 million people annually, and claims over 500,000 lives, so an urgent need exists for a vaccine against GAS.

In , Malmström’s lab has shown that GAS forms extensive protein interaction networks with human proteins, so they wanted to analyze the association between the antigen-specific antibody responses and the host protein–bacterial protein interactions. They also wanted to understand if antigen-specific antibody responses could affect these protein networks to understand antibody repertoire (the entire set of antibodies produced in an individual), ultimately aiding the development of effective vaccines against GAS.

In this study, the researchers immunized mice with the conserved M1 protein from GAS and showed that mouse plasma protein forms similar protein networks with the bacterial M1 protein as those seen in humans. Using AP-MS, they quantified the competition among antibodies and protein interaction networks.

While the team found that the antigen targeted by the anti-M1 antibodies affected sites outside the protein interaction surfaces and could not outcompete these interactions, they also discovered in this study that regions in bacterial proteins within protein-interaction interfaces are more challenging to develop antibodies against, highlighting the need to quantify and assess these interactions.

Several bacterial pathogens use their surface proteins to interact with the host proteins to dodge the immune system and mask their dominant epitopes.

The experimental strategy developed in this study can measure the level of competition between antibodies and host plasma proteins at the same bacterial sites, thereby dictating the course of host immune responses. This method could be broadly applicable to any type of bacterial protein.

“I think that the most efficient way forward would be to build networks of scientists with different research skills and meet around the same problem,” Malmström said.

Read more about this group’s research .

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Poornima Sankar

Poornima Sankar is a graduate student at the Department of Immunology and Microbial Disease at Albany Medical Center. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How sugars shape Marfan syndrome
Journal News

How sugars shape Marfan syndrome

Sept. 10, 2025

Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent paper.